R H Weiss

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Attenuation of matrix protein secretion by antisense oligodeoxynucleotides to the cyclin kinase inhibitor p21(Waf1/Cip1)
    Robert H Weiss
    Division of Nephrology, Department of Internal Medicine, TB 136 University of California, Davis, CA 95616, USA
    Atherosclerosis 161:105-12. 2002
  2. ncbi request reprint p21Waf1/Cip1 as a therapeutic target in breast and other cancers
    Robert H Weiss
    Division of Nephrology, Department of Internal Medicine and Cancer Center University of California, Davis, California 95616, USA
    Cancer Cell 4:425-9. 2003
  3. pmc p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels
    Jin Young Park
    Immunology Graduate Group, University of California, Davis, CA, USA
    BMC Nephrol 8:12. 2007
  4. pmc Mealtime, temporal, and daily variability of the human urinary and plasma metabolomes in a tightly controlled environment
    Kyoungmi Kim
    Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, Davis, California, United States of America
    PLoS ONE 9:e86223. 2014
  5. pmc Inhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells
    Omran Abu Aboud
    Division of Nephrology, Department of Internal Medicine, University of California Davis, Davis, California, United States of America
    PLoS ONE 8:e71115. 2013
  6. pmc Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance
    Pei yin Lin
    Division of Nephrology, Department of Internal Medicine, University of California, Davis, CA, USA
    Mol Cancer 6:16. 2007
  7. pmc Pathway analysis of kidney cancer using proteomics and metabolic profiling
    Bertrand Perroud
    Genome Center, University of California, Davis, CA, USA
    Mol Cancer 5:64. 2006
  8. ncbi request reprint G protein-coupled receptor signalling in the kidney
    R H Weiss
    Department of Internal Medicine, University of California, Davis 95616, USA
    Cell Signal 10:313-20. 1998
  9. ncbi request reprint Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase
    R H Weiss
    Department of Internal Medicine, University of California, Davis 95616, USA
    J Am Soc Nephrol 10:1880-90. 1999
  10. doi request reprint Metabolomics in the study of kidney diseases
    Robert H Weiss
    Division of Nephrology, Department of Internal Medicine, Genome and Biomedical Sciences Building, Room 6312, University of California, Davis, CA 95616, USA
    Nat Rev Nephrol 8:22-33. 2012

Collaborators

Detail Information

Publications33

  1. ncbi request reprint Attenuation of matrix protein secretion by antisense oligodeoxynucleotides to the cyclin kinase inhibitor p21(Waf1/Cip1)
    Robert H Weiss
    Division of Nephrology, Department of Internal Medicine, TB 136 University of California, Davis, CA 95616, USA
    Atherosclerosis 161:105-12. 2002
    ....
  2. ncbi request reprint p21Waf1/Cip1 as a therapeutic target in breast and other cancers
    Robert H Weiss
    Division of Nephrology, Department of Internal Medicine and Cancer Center University of California, Davis, California 95616, USA
    Cancer Cell 4:425-9. 2003
    ....
  3. pmc p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels
    Jin Young Park
    Immunology Graduate Group, University of California, Davis, CA, USA
    BMC Nephrol 8:12. 2007
    ....
  4. pmc Mealtime, temporal, and daily variability of the human urinary and plasma metabolomes in a tightly controlled environment
    Kyoungmi Kim
    Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, Davis, California, United States of America
    PLoS ONE 9:e86223. 2014
    ..In light of these findings, future metabolomics studies should consider these sources of variability to allow for appropriate metabolomics testing and reliable clinical translation of metabolomics data. ..
  5. pmc Inhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells
    Omran Abu Aboud
    Division of Nephrology, Department of Internal Medicine, University of California Davis, Davis, California, United States of America
    PLoS ONE 8:e71115. 2013
    ....
  6. pmc Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance
    Pei yin Lin
    Division of Nephrology, Department of Internal Medicine, University of California, Davis, CA, USA
    Mol Cancer 6:16. 2007
    ..Renal cell carcinoma (RCC) is associated with frequent treatment failures (approximately 90% in metastatic cases), and these tumors frequently contain PTEN abnormalities...
  7. pmc Pathway analysis of kidney cancer using proteomics and metabolic profiling
    Bertrand Perroud
    Genome Center, University of California, Davis, CA, USA
    Mol Cancer 5:64. 2006
    ....
  8. ncbi request reprint G protein-coupled receptor signalling in the kidney
    R H Weiss
    Department of Internal Medicine, University of California, Davis 95616, USA
    Cell Signal 10:313-20. 1998
    ..In this review, several G protein-coupled receptors will be discussed from the perspective of their importance to kidney function and to the pathogenesis of renal disease, atherosclerosis, and hypertension...
  9. ncbi request reprint Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase
    R H Weiss
    Department of Internal Medicine, University of California, Davis 95616, USA
    J Am Soc Nephrol 10:1880-90. 1999
    ....
  10. doi request reprint Metabolomics in the study of kidney diseases
    Robert H Weiss
    Division of Nephrology, Department of Internal Medicine, Genome and Biomedical Sciences Building, Room 6312, University of California, Davis, CA 95616, USA
    Nat Rev Nephrol 8:22-33. 2012
    ..Thus, metabolomics holds promise for early diagnosis, increased choice of therapy and the identification of new metabolic pathways that could potentially be targeted in kidney disease...
  11. ncbi request reprint p21(Waf1/Cip1) is an assembly factor required for platelet-derived growth factor-induced vascular smooth muscle cell proliferation
    R H Weiss
    Division of Nephrology, Department of Internal Medicine, University of California, Davis, California 95616, USA
    J Biol Chem 275:10285-90. 2000
    ....
  12. ncbi request reprint p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches
    Robert H Weiss
    Division of Nephrology, Department of Internal Medicine, University of California, Davis, California 95616, USA
    J Urol 177:63-8; discussion 68-9. 2007
    ..The apoptosis and cell cycle regulatory protein, p21(waf1/cip1), has been investigated as a possible target in other cancers since it is involved in the repair and apoptotic response of normal and malignant cells to DNA damage...
  13. ncbi request reprint The permissive effect of p21(Waf1/Cip1) on DNA synthesis is dependent on cell type: effect is absent in p53-inactive cells
    R H Weiss
    Division of Nephrology, Department of Internal Medicine, University of California, Davis, CA 95616, USA
    Cell Signal 12:413-8. 2000
    ..Thus, the permissive effect of p21(Waf1/Cip1) toward growth is dependent on cell type, and active p53 is likely required for this effect...
  14. ncbi request reprint Kidney cancer: identification of novel targets for therapy
    R H Weiss
    Department of Internal Medicine and Cancer Center, Division of Nephrology, University of California, Davis, California 95616, USA
    Kidney Int 69:224-32. 2006
    ..In this review, we summarize the current state of kidney cancer diagnosis and therapy, as well as some of the novel treatments that capitalize on those newly elucidated molecular pathways that are deranged in this disease...
  15. ncbi request reprint p73 is a growth-regulated protein in vascular smooth muscle cells and is present at high levels in human atherosclerotic plaque
    R H Weiss
    Division of Nephrology, Department of Internal Medicine, University of California, Davis, 95616, USA
    Cell Signal 13:727-33. 2001
    ....
  16. ncbi request reprint Suppression of breast cancer growth and angiogenesis by an antisense oligodeoxynucleotide to p21(Waf1/Cip1)
    Robert H Weiss
    Division of Nephrology, Department of Internal Medicine, University of California, Davis, CA 95616, USA
    Cancer Lett 189:39-48. 2003
    ....
  17. ncbi request reprint TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27
    C J Hupfeld
    Division of Endocrinology, Department of Internal Medicine, University of California, Davis, California 95616, USA
    Am J Physiol Endocrinol Metab 281:E207-16. 2001
    ..The observed decrease in levels of the G1 cyclins by the TZDs suggests a possible mechanism of VSM cell growth inhibition...
  18. pmc Disparate effects of roscovitine on renal tubular epithelial cell apoptosis and senescence: implications for autosomal dominant polycystic kidney disease
    Jin Young Park
    Division of Nephrology, Department of Internal Medicine, University of California, Davis, CA 95616, USA
    Am J Nephrol 29:509-15. 2009
    ..The cyclin kinase inhibitor roscovitine has shown efficacy in treatment of murine PKD. We asked how a single agent can be efficacious in both PKD and cancer...
  19. ncbi request reprint High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers
    See Hyoung Park
    Division of Nephrology, University of California, Davis, California 95616, USA
    Cancer Biol Ther 7:2015-22. 2008
    ..These compounds are currently being evaluated in in vivo assays as potential novel therapeutic for RCC...
  20. ncbi request reprint Targeting the PI3K-Akt pathway in kidney cancer
    Jin Young Park
    Division of Nephrology, Department of Internal Medicine, Immunology Graduate Group, University of California, Davis, CA 95616, USA
    Expert Rev Anticancer Ther 7:863-70. 2007
    ..In this review, we discuss PI3K-Akt inhibitors as well as inhibitors of pathways and targets both immediately up- and downstream of this cascade, many of which show promise in the clinic...
  21. ncbi request reprint BMP-2 inhibits proliferation of human aortic smooth muscle cells via p21Cip1/Waf1
    Gail A Wong
    Department of Internal Medicine, Division of Endocrinology, Clinical Nutrition and Vascular Medicine, University of California Davis, UC Davis Medical Center, 4150 V Street, PSSB G400, Sacramento, CA 95817, USA
    Am J Physiol Endocrinol Metab 284:E972-9. 2003
    ..Whether p21-mediated induction of cell cycle arrest by BMP-2 sets the stage for osteogenic differentiation of vascular smooth muscle cells, ultimately leading to vascular mineralization, remains to be investigated...
  22. doi request reprint Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma
    Tatsuto Ishimaru
    Division of Nephrology, Department of Internal Medicine and Cancer Center, University of California Davis, Davis, California 95616, USA
    J Urol 184:2143-9. 2010
    ..We evaluated the effect of roscovitine (Sigma-Aldrich®), a pharmacological inhibitor of cyclin dependent kinase, on renal cell carcinoma cell lines in vitro...
  23. pmc Grade-dependent proteomics characterization of kidney cancer
    Bertrand Perroud
    Genome Center, Department of Internal Medicine, University of California, Davis, California 95616, USA
    Mol Cell Proteomics 8:971-85. 2009
    ....
  24. pmc Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53
    See Hyoung Park
    Division of Nephrology, Department of Internal Medicine and Cancer Center, University of California, Davis, California 95616, USA
    J Urol 180:352-60. 2008
    ..We capitalized on this function of p21 and used an antisense approach to sensitize p53-wt renal cell carcinoma cells to chemotherapy induced apoptosis by attenuating p21 protein levels...
  25. ncbi request reprint An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells
    Yaping Fan
    Division of Nephrology, Department of Internal Medicine, University of California, Davis, California 95616, USA
    Mol Cancer Ther 2:773-82. 2003
    ....
  26. ncbi request reprint Cytosolic p21Waf1/Cip1 increases cell cycle transit in vascular smooth muscle cells
    Yao Dong
    Division of Nephrology, Department of Internal Medicine, University of California, Davis, CA 95616, USA
    Cell Signal 16:263-9. 2004
    ..Furthermore, compartmentalization of p21 may help explain the biphasic nature of p21 in a variety of cell types and may lead to therapeutic advances directed at modulating pathologic cell growth in vascular diseases and cancer...
  27. ncbi request reprint A comprehensive urinary metabolomic approach for identifying kidney cancerr
    Tobias Kind
    Genome Center, University of California, Davis, CA 95616, USA
    Anal Biochem 363:185-95. 2007
    ..Such investigation will likely lead to clinically applicable assays for earlier diagnosis of RCC, as well as other malignancies, and thereby improved patient prognosis...
  28. pmc Urine metabolomics analysis for kidney cancer detection and biomarker discovery
    Kyoungmi Kim
    Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, California 95616, USA
    Mol Cell Proteomics 8:558-70. 2009
    ....
  29. pmc Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation
    Benjamin B Davis
    Division of Nephrology, Department of Internal Medicine, University of California, Davis, CA 95616, USA
    Proc Natl Acad Sci U S A 99:2222-7. 2002
    ....
  30. pmc Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition
    Benjamin B Davis
    Division of Nephrology, Department of Internal Medicine, University of California, Davis, 95616, USA
    J Pharmacol Exp Ther 316:815-21. 2006
    ..In addition, our results show that caution should be used when attempting to infer conclusions of EET biology based solely on the effects these inhibitors in tissue culture models, especially when used at micromolar concentrations...
  31. ncbi request reprint Exogenous attenuation of p21(Waf1/Cip1) decreases mesangial cell hypertrophy as a result of hyperglycemia and IGF-1
    Ya Ping Fan
    Division of Nephrology, Department of Internal Medicine and Cancer Center, University of California, Davis, CA 95616, USA
    J Am Soc Nephrol 15:575-84. 2004
    ....
  32. pmc Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo
    Jun Yan Liu
    Division of Nephrology, Department of Internal Medicine, Genome and Biomedical Sciences Facility, University of California, Davis, California 95616, USA
    Mol Cancer Ther 8:2193-203. 2009
    ..Thus, it is likely that soluble epoxide hydrolase inhibition contributes to the beneficial effects from the inhibition of the VEGF receptor and other kinases during treatment with sorafenib...
  33. pmc A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease
    Sandra L Taylor
    Division of Biostatistics, Department of Public Health Sciences, University of California Davis, Davis, CA 95616, USA
    Am J Physiol Renal Physiol 298:F909-22. 2010
    ..Thus, urine metabolomics has great diagnostic potential for cystic renal disorders and deserves further study...

Research Grants4

  1. A Metabolomic Approach to Discovering Biomarkers for ADPKD
    Robert Weiss; Fiscal Year: 2009
    ..In addition, work from this proposal will lead to new knowledge about the pathology of the disease and to selection of patients who will most benefit from any new drug. ..
  2. Metabolomic discovery and validation of urinary biomarkers for kidney cancer
    Robert H Weiss; Fiscal Year: 2010
    ....
  3. A Metabolomic Approach to Discovering Biomarkers for ADPKD
    Robert H Weiss; Fiscal Year: 2010
    ..In addition, work from this proposal will lead to new knowledge about the pathology of the disease and to selection of patients who will most benefit from any new drug. ..
  4. Metabolomic discovery and validation of urinary biomarkers for kidney cancer
    Robert Weiss; Fiscal Year: 2009
    ....